The Pharmaceutical Journal
Vol 274 No 7340 p289
12 March 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Avandamet shortages likely after manufacture problems

Avandamet, GlaxoSmithKline’s recently launched type 2 diabetes treatment, is expected to be in short supply in the UK within the next two weeks. A GSK spokesman confirmed that quality control problems were disrupting manufacture in Puerto Rico.

The problem came to light last week when the US Food and Drug Administration seized batches of Avandamet that did not contain the right amount of rosiglitazone, one of the active ingredients.